Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 5.61B 5.02B 4.62B 4.19B 7.83B 533B 7.97B 55.11B 22.12B 280B 21.05B 20.6B 884B P/E 2026 *
-5.72x
P/E 2027 * -135x
Enterprise Value 5.8B 5.19B 4.78B 4.33B 8.09B 551B 8.24B 56.96B 22.87B 290B 21.76B 21.3B 913B EV / Sales 2026 *
8.31x
EV / Sales 2027 * 6.95x
Free-Float
98.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mirum Pharmaceuticals, Inc.

1 day-2.26%
1 week+4.83%
Current month-1.41%
1 month-1.41%
3 months-25.15%
6 months-13.40%
Current year+6.69%
1 week 81.16
Extreme 81.16
88.51
1 month 77.78
Extreme 77.78
88.51
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Free

Chief Technology Officer

65,000 0.1001%
10/6/26 Exercice

Founder

24,394 0.0376%
9/21/26 Other

Chief Technology Officer

55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%+4.83%+16.72%+209.27% 5.61B
+3.22%+11.29%+67.82%+150.53% 1,224B
-0.24%+4.07%+45.22%+86.72% 662B
+1.21%+3.08%+29.02%+107.50% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.35%+3.14%+73.65%+45.92% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.31%+6.14%+59.67%+77.15% 249B
+3.54%+9.64%+44.45%+119.99% 205B
Average +1.79%+2.73%+43.73%+95.89% 418.25B
Weighted average by Cap. +2.09%+3.04%+50.99%+98.52%

Financials

2026 *2027 *
Net sales 698M 625M 575M 521M 974M 66.29B 992M 6.86B 2.75B 34.87B 2.62B 2.56B 110B 820M 734M 675M 612M 1.14B 77.82B 1.16B 8.05B 3.23B 40.94B 3.08B 3.01B 129B
Net income -928M -831M -764M -692M -1.29B -88.09B -1.32B -9.11B -3.66B -46.34B -3.48B -3.41B -146B -47.05M -42.14M -38.76M -35.12M -65.64M -4.47B -66.87M -462M -186M -2.35B -177M -173M -7.41B
Net Debt 189M 169M 156M 141M 264M 17.95B 269M 1.86B 745M 9.44B 709M 694M 29.77B 82.62M 73.99M 68.06M 61.67M 115M 7.84B 117M 812M 326M 4.13B 310M 303M 13.01B
Projected Income Statement - Annual - Mirum Pharmaceuticals, Inc.
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
26-10-30 US$84.22 -2.52% 345,775
26-10-29 US$86.39 +0.68% 591,322
26-10-28 US$85.81 +0.29% 535,232
26-10-27 US$85.56 +2.75% 563,279
26-10-26 US$83.27 +3.58% 429,983
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Mirum Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
86.39USD
Average target price
153.43USD
Spread / Average Target
+77.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mirum Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MIRM Stock